|Videos|March 16, 2021
Evaluating Dementia Interventions, Areas of Improvement: XinQi Dong, MD, MPH
Author(s)XinQi Dong, MD, MPH
The director of the Institute for Health, Health Care Policy, and Aging Research at Rutgers University discussed his recent findings on assessing evidence for dementia care interventions.
Advertisement
"Another focus is on the outcomes that are most important for a person living with dementia and their caregivers. Understanding issues relating to intended and unintended benefits and harm. Every intervention has a lot of intended benefits they hope to measure, but sometimes those unintended benefits can occur and cause harm.”
A committee of expert dementia care specialists recently convened to publish a report on the challenges of caring for persons with dementia and their care partners and caregivers. They assessed the state of evidence for dementia interventions and provided thoughts on interventions ready for implementation in real-world settings.
XinQi Dong, MD, MPH, director of the Institute for Health, Health Care Policy, and Aging Research at Rutgers University , was among those involved with the report. He and his colleagues provided principles that can guide ideal care, services, and supports for persons living with dementia and their caregivers. Among them included person-centeredness, justice, promotion of well-being, respect and dignity, accessibility and affordability, and racial, ethnic, sexual, cultural, and linguistic inclusivity.
In an interview with NeurologyLive, Dong discussed the report in full, including what the top-level conclusions the data draw. He also detailed each of the recommendations that he and his colleagues laid out and why they are necessary to improve dementia interventions.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
Expanding the Alzheimer Drug Development Pipeline
2
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
3
FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency
4
NeurologyLive® Friday 5 — September 12, 2025
5